Descrizione

A rare disease, also referred to as an orphan disease, is any disease that affects a small percentage of the population. There are thousands of rare diseases. To date, six to seven thousand rare diseases have been discovered and new diseases are regularly described in medical literature. The global rare disease diagnostics market in terms of revenue is set to grow by US$ 12 miliardi durante 2021-2027, crescendo ad un tasso di crescita annuale composto (CAGR) Di 8.6% durante il periodo di previsione, secondo la società di dati e analisi StrategyHelix. Rising burden of diseases and increase in incidence and prevalence of genetic disorders and various types of cancer, increase in adoption of whole genome and exome sequencing, and increasing research funding and surge in usage for new techniques are driving market growth.

Il rapporto fornisce dati aggiornati sulle dimensioni del mercato per il periodo 2017-2020 e previsione a 2027 covering key market aspects like sales value for rare disease diagnostics. The global rare disease diagnostics market is segmented on the basis of disease, tecnologia, age, analysis target, e regione. By disease, it is categorized into cardiovascular, central nervous system, endocrine and metabolic, hematology, immune and inflammation, rare cancers, and other diseases. The diagnostics for rare cancers segment held the largest market share in 2020. Per tecnologia, the rare disease diagnostics market is divided into polymerase chain reaction (PCR), next-generation sequencing, microarrays, e altri. Based on age, the rare disease diagnostics market is divided into children, and adult. Rare disease diagnostics market by analysis target is divided into multiple genes, whole exome, single genes, and whole genome.

The report has profiled some of the key players of the market such as 3billion Inc., Agilent Technologies Inc., BGI Group, Centogene AG, Eurofins Scientific SE, Illumina Inc., Invitae Corporation, Laboratory Corporation of America Holdings, PerkinElmer Inc., Quest Diagnostics Incorporated.

Il rapporto è una risorsa inestimabile per le aziende e le organizzazioni attive in questo settore. It provides a cohesive picture of the rare disease diagnostics market to help drive informed decision making for industry executives, decisori politici, accademico, e analisti.

Ambito del rapporto

Disease: cardiovascular, central nervous system, endocrine and metabolic, hematology, immune and inflammation, rare cancers, and other diseases
Tecnologia: polymerase chain reaction (PCR), next-generation sequencing, microarrays, e altri
Age: children, and adult
Regione: Nord America, Asia Pacifico, Europa, and Rest of the World (ROW)
Analysis target: multiple genes, whole exome, single genes, and whole genome
Anni considerati: la presente relazione copre il periodo 2017 A 2027

Principali vantaggi per gli stakeholder

Get a comprehensive picture of the global rare disease diagnostics market
Identificare le strategie regionali e le priorità strategiche sulla base di dati e analisi locali
Individuare i settori in crescita e le tendenze per gli investimenti
Understand what the future of the global rare disease diagnostics market looks like
Identificare il panorama competitivo e la finestra di opportunità

Sommario

1. Definizione del mercato
2. Metodologia di ricerca
3. Dati di mercato & Veduta
3.1 Valore di mercato
3.2 Previsione del valore di mercato
4. Rare Disease Diagnostics Market by Disease
4.1 Cardiovascular
4.2 Central Nervous System
4.3 Endocrine And Metabolic
4.4 Hematology
4.5 Immune And Inflammation
4.6 Rare Cancers
4.7 Other Diseases
5. Rare Disease Diagnostics Market by Technology
5.1 Polymerase Chain Reaction (Pcr)
5.2 Next-Generation Sequencing
5.3 Microarrays
5.4 Altri
6. Rare Disease Diagnostics Market by Age
6.1 Children
6.2 Adult
7. Rare Disease Diagnostics Market by Analysis Target
7.1 Multiple Genes
7.2 Whole Exome
7.3 Single Genes
7.4 Whole Genome
8. Rare Disease Diagnostics Market by Region
8.1 Nord America
8.2 Asia Pacifico
8.3 Europa
8.4 Rest Of The World (Row)
9. Profili aziendali
9.1 3billion Inc.
9.2 Agilent Technologies Inc.
9.3 BGI Group
9.4 Centogene AG
9.5 Eurofins Scientific SE
9.6 Illumina Inc.
9.7 Invitae Corporation
9.8 Laboratory Corporation of America Holdings
9.9 PerkinElmer, Inc.
9.10 Quest Diagnostics Incorporated
10. Appendice
10.1 Informazioni su StrategyHelix
10.2 Disclaimer